Adenoviral delivery of vegf promotes short term angiogenic effect

Matthew J. Gounis; Baruch B. Lieber; Keith A. Webster; M. Grazia Spiga; Nanette H. Bishopric; Ajay K. Wakhloo

Adenoviral delivery of vegf promotes short term angiogenic effect

Matthew J. Gounis, Baruch B. Lieber, Keith A. Webster, M. Grazia Spiga, Nanette H. Bishopric, Ajay K. Wakhloo

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution

Abstract

A longitudinal in vivo study has been completed to evaluate the angiogenic benefit of an adenoviral vector used to express vascular endothelial growth factor (VEGF ₁₆₅). Subsequently, numerous methods of therapeutic angiogenesis, including different gene delivery vehicles as well as the route of administration of these vectors, have been studied using angiographic time-intensity data. Mathematical modeling of these data provides indices of the formation and function of new vessel growth in response to the treatment modality. The angiographic and immunohistological results demonstrate that adenoviral (Ad) delivery of VEGF promotes a rapid angiogenic effect within the first week of treatment. However, this effect is not sustained and returns to control levels within three weeks. These results support the conclusion that Ad mediated therapeutic angiogenesis may not provide long term benefit.

Original language	English (US)
Title of host publication	Proceedings of the 2005 Summer Bioengineering Conference, 2005 SBC
Pages	709-710
Number of pages	2
State	Published - Dec 1 2005
Event	2005 Summer Bioengineering Conference - Vail, CO, United States Duration: Jun 22 2005 → Jun 26 2005

Publication series

Name	Proceedings of the 2005 Summer Bioengineering Conference
Volume	2005

Other

Other	2005 Summer Bioengineering Conference
Country	United States
City	Vail, CO
Period	6/22/05 → 6/26/05

ASJC Scopus subject areas

Engineering(all)

Access to Document

Fingerprint Dive into the research topics of 'Adenoviral delivery of vegf promotes short term angiogenic effect'. Together they form a unique fingerprint.

Cite this

Gounis, M. J., Lieber, B. B., Webster, K. A., Spiga, M. G., Bishopric, N. H., & Wakhloo, A. K. (2005). Adenoviral delivery of vegf promotes short term angiogenic effect. In Proceedings of the 2005 Summer Bioengineering Conference, 2005 SBC (pp. 709-710). (Proceedings of the 2005 Summer Bioengineering Conference; Vol. 2005).

Adenoviral delivery of vegf promotes short term angiogenic effect. / Gounis, Matthew J.; Lieber, Baruch B.; Webster, Keith A.; Spiga, M. Grazia; Bishopric, Nanette H.; Wakhloo, Ajay K.

Proceedings of the 2005 Summer Bioengineering Conference, 2005 SBC. 2005. p. 709-710 (Proceedings of the 2005 Summer Bioengineering Conference; Vol. 2005).

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution

Gounis, MJ, Lieber, BB, Webster, KA, Spiga, MG, Bishopric, NH & Wakhloo, AK 2005, Adenoviral delivery of vegf promotes short term angiogenic effect. in Proceedings of the 2005 Summer Bioengineering Conference, 2005 SBC. Proceedings of the 2005 Summer Bioengineering Conference, vol. 2005, pp. 709-710, 2005 Summer Bioengineering Conference, Vail, CO, United States, 6/22/05.

@inproceedings{7f7f5f5321814a1e9aa43e745be9847b,

title = "Adenoviral delivery of vegf promotes short term angiogenic effect",

abstract = "A longitudinal in vivo study has been completed to evaluate the angiogenic benefit of an adenoviral vector used to express vascular endothelial growth factor (VEGF 165). Subsequently, numerous methods of therapeutic angiogenesis, including different gene delivery vehicles as well as the route of administration of these vectors, have been studied using angiographic time-intensity data. Mathematical modeling of these data provides indices of the formation and function of new vessel growth in response to the treatment modality. The angiographic and immunohistological results demonstrate that adenoviral (Ad) delivery of VEGF promotes a rapid angiogenic effect within the first week of treatment. However, this effect is not sustained and returns to control levels within three weeks. These results support the conclusion that Ad mediated therapeutic angiogenesis may not provide long term benefit.",

author = "Gounis, {Matthew J.} and Lieber, {Baruch B.} and Webster, {Keith A.} and Spiga, {M. Grazia} and Bishopric, {Nanette H.} and Wakhloo, {Ajay K.}",

year = "2005",

month = dec,

day = "1",

language = "English (US)",

isbn = "0974249211",

series = "Proceedings of the 2005 Summer Bioengineering Conference",

pages = "709--710",

booktitle = "Proceedings of the 2005 Summer Bioengineering Conference, 2005 SBC",

note = "2005 Summer Bioengineering Conference ; Conference date: 22-06-2005 Through 26-06-2005",

}

TY - GEN

T1 - Adenoviral delivery of vegf promotes short term angiogenic effect

AU - Gounis, Matthew J.

AU - Lieber, Baruch B.

AU - Webster, Keith A.

AU - Spiga, M. Grazia

AU - Bishopric, Nanette H.

AU - Wakhloo, Ajay K.

PY - 2005/12/1

Y1 - 2005/12/1

N2 - A longitudinal in vivo study has been completed to evaluate the angiogenic benefit of an adenoviral vector used to express vascular endothelial growth factor (VEGF 165). Subsequently, numerous methods of therapeutic angiogenesis, including different gene delivery vehicles as well as the route of administration of these vectors, have been studied using angiographic time-intensity data. Mathematical modeling of these data provides indices of the formation and function of new vessel growth in response to the treatment modality. The angiographic and immunohistological results demonstrate that adenoviral (Ad) delivery of VEGF promotes a rapid angiogenic effect within the first week of treatment. However, this effect is not sustained and returns to control levels within three weeks. These results support the conclusion that Ad mediated therapeutic angiogenesis may not provide long term benefit.

AB - A longitudinal in vivo study has been completed to evaluate the angiogenic benefit of an adenoviral vector used to express vascular endothelial growth factor (VEGF 165). Subsequently, numerous methods of therapeutic angiogenesis, including different gene delivery vehicles as well as the route of administration of these vectors, have been studied using angiographic time-intensity data. Mathematical modeling of these data provides indices of the formation and function of new vessel growth in response to the treatment modality. The angiographic and immunohistological results demonstrate that adenoviral (Ad) delivery of VEGF promotes a rapid angiogenic effect within the first week of treatment. However, this effect is not sustained and returns to control levels within three weeks. These results support the conclusion that Ad mediated therapeutic angiogenesis may not provide long term benefit.

UR - http://www.scopus.com/inward/record.url?scp=33646582615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646582615&partnerID=8YFLogxK

M3 - Conference contribution

AN - SCOPUS:33646582615

SN - 0974249211

SN - 9780974249216

T3 - Proceedings of the 2005 Summer Bioengineering Conference

SP - 709

EP - 710

BT - Proceedings of the 2005 Summer Bioengineering Conference, 2005 SBC

T2 - 2005 Summer Bioengineering Conference

Y2 - 22 June 2005 through 26 June 2005

ER -